Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H12ClN3O4S2 |
Molecular Weight | 385.846 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)NC2=C3NC=C(Cl)C3=CC=C2
InChI
InChIKey=SETFNECMODOHTO-UHFFFAOYSA-N
InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)
Molecular Formula | C14H12ClN3O4S2 |
Molecular Weight | 385.846 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Indisulam (also known as E7070) is a sulfonamide derivative patented by Japanese pharmaceutical company Eisai Co. as antitumor agent. Indisulam inhibits cyclin-dependent kinases (CDK), which regulate cell cycle progression and are usually over-expressed in cancerous cells. Inhibition of CDK results in G1/S phase arrest of the cell cycle, and may lead to induction of apoptosis and inhibition of tumor cell proliferation. Preclinical and clinical studies have established the synergy of indisulam with nucleoside analogs as well as topoisomerase inhibitors. These combinations were tolerated with acceptable toxicities, including diarrhea, vomiting, and myelosuppression. In Phase II clinical trials Combination of indisulam with DNA‐damaging agent (idarubicin) and nucleoside analog (cytarabine) in patients with relapsed and refractory AML is effective and largely well tolerated.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14698154 |
31.0 nM [IC50] | ||
Target ID: CHEMBL3025 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17228881 |
47.0 nM [Ki] | ||
Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14698154 |
15.0 nM [IC50] | ||
Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17228881 |
24.0 nM [Ki] |
PubMed
Title | Date | PubMed |
---|---|---|
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide). | 2002 Nov |
|
Quantitative chemical proteomics for identifying candidate drug targets. | 2003 May 1 |
|
Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | 2004 |
|
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. | 2005 Jun |
|
Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. | 2006 Jun |
|
A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. | 2006 Oct |
|
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. | 2008 Apr 22 |
|
Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. | 2009 Feb |
|
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety. | 2013 Oct 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29660836
400 mg/ m^2 on days 1 and 8 of a 28-day cycle
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:40:43 GMT 2023
by
admin
on
Fri Dec 15 15:40:43 GMT 2023
|
Record UNII |
WJ98J3NM90
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29577
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
||
|
NCI_THESAURUS |
C2185
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C25797
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
145431
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
SUB121367
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
WJ98J3NM90
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
100000144620
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL77517
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
E7070
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
8199
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
216468
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
m6256
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
165668-41-7
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
DB06370
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
RR-50
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY | |||
|
DTXSID50168008
Created by
admin on Fri Dec 15 15:40:43 GMT 2023 , Edited by admin on Fri Dec 15 15:40:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->DEGRADER |
Indisulam induces a ternary protein complex between RNA Binding Motif 39 (RBM39) and the E3 ubiquitin ligase receptor DDB1 and CUL4 associated factor 15 (DCAF15) resulting in rapid proteasomal degradation of RBM39, aberrant RNA splicing and cell death.
|
||
|
TARGET->DEGRADER |
Indisulam induces a ternary protein complex between RNA Binding Motif 39 (RBM39) and the E3 ubiquitin ligase receptor DDB1 and CUL4 associated factor 15 (DCAF15) resulting in rapid proteasomal degradation of RBM39, aberrant RNA splicing and cell death.
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|